Product
Supplier
Encyclopedia
Inquiry
Home > News > Market Flash > DRL Announces The Launch Of Anti-Allergy Drug In US Market

DRL Announces The Launch Of Anti-Allergy Drug In US Market

Chemical Weekly 2018-03-29

Dr. Reddy’s Laboratories Ltd. (DRL) has announced that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of Xyzal Allergy 24HR Tablets, from UCB, in the US market as approved by the US FDA. The drug is an over-the-counter antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing.

“This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,” said Mr. Milan Kalawadia, Vice President and Head, US Over-the-Counter and Speciality Rx businesses, DRL.

The Xyzal Allergy 24HR Tablets brand had US sales of approximately $71-mn for the most recent twelve months ending in January 2018.

 

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.
Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.